Related references
Note: Only part of the references are listed.ROS1-dependent cancers - biology, diagnostics and therapeutics
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC).
Arvind Dasari et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The efficacy and safety of anlotinib in refractory colorectal cancer: A double-blinded, placebo controlled, randomized phase III ALTER0703 trial.
Yihebali Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
Josep Tabernero et al.
FUTURE ONCOLOGY (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
Romain Cohen et al.
CANCERS (2021)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset
V. Boni et al.
ANNALS OF ONCOLOGY (2021)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
Takayuki Yoshino et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.
Giulia Martini et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report
Xi He et al.
JCO PRECISION ONCOLOGY (2021)
Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
Sheng-Yen Hsiao et al.
CASE REPORTS IN ONCOLOGY (2021)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer (AGICC 17CRC01).
Aaron James Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer et al.
LANCET ONCOLOGY (2020)
NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases
Angela Chou et al.
MODERN PATHOLOGY (2020)
Targeting the MAPK Pathway in KRAS-Driven Tumors
Matthias Drosten et al.
CANCER CELL (2020)
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
Daniele Rossini et al.
CLINICAL COLORECTAL CANCER (2020)
Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
Fen Wang et al.
SCIENTIFIC REPORTS (2020)
Colorectal Adenocarcinomas Harboring ALK Fusion Genes A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature
Jerzy Lasota et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2020)
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
Federica Tosi et al.
CLINICAL COLORECTAL CANCER (2020)
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial
Giuseppe Pasqualetti et al.
EUROPEAN JOURNAL OF CANCER (2020)
Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
Qian Yang et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)
K. Ding et al.
ANNALS OF ONCOLOGY (2020)
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment inKRASwild-type metastatic colorectal cancer: JACCRO CC-08
Toshiki Masuishi et al.
BRITISH JOURNAL OF CANCER (2020)
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
M.L. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2020)
NELL2-mediated lumicrine signaling through OVCH2 is required for male fertility
Daiji Kiyozumi et al.
SCIENCE (2020)
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Yoshiaki Nakamura et al.
NATURE MEDICINE (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
Josep Tabernero et al.
ESMO OPEN (2020)
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
Alberto D'Angelo et al.
CANCERS (2020)
Multiple treatment lines and prognosis in metastatic colorectal cancer patients
Chiara Carlomagno et al.
CANCER AND METASTASIS REVIEWS (2019)
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem et al.
ONCOLOGIST (2019)
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Asghar Fallah et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Giulia Siravegna et al.
CLINICAL CANCER RESEARCH (2019)
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Lorenza Rimassa et al.
CLINICAL COLORECTAL CANCER (2019)
Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial-Final results from the randomized phase II trial of the AIO.
Thomas Jens Ettrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
Hiroki Osumi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
O-026Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)
G Argiles et al.
ANNALS OF ONCOLOGY (2019)
A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer
Mohamad Bassam Sonbol et al.
ONCOLOGIST (2019)
Fruquintinib and its use in the treatment of metastatic colorectal cancer
Yanhong Deng et al.
FUTURE ONCOLOGY (2019)
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S. Bekaii-Saab et al.
LANCET ONCOLOGY (2019)
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco et al.
NATURE MEDICINE (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO
D. Rossini et al.
ANNALS OF ONCOLOGY (2019)
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A. Amatu et al.
ANNALS OF ONCOLOGY (2019)
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C. M. Parseghian et al.
ANNALS OF ONCOLOGY (2019)
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Muhammad Khan et al.
FRONTIERS IN ONCOLOGY (2019)
Decreased percentage of neutrophil is a predict factor for the efficacy of trifluridine and tipiracil hydrochloride for pretreated metastatic colorectal cancer
Katsuya Makihara et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
S. Siena et al.
ANNALS OF ONCOLOGY (2018)
Nintedanib for the treatment of patients win refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized placebo-controlled study
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2018)
A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis
Ana B. K. Abrahao et al.
CLINICAL COLORECTAL CANCER (2018)
Regorafenib: A Review in Metastatic Colorectal Cancer
Sohita Dhillon
DRUGS (2018)
Anlotinib inhibits angiogenesis &ITvia&IT suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Binyan Lin et al.
GENE (2018)
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
Jin Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Results of a Randomized, Double- Blind, Placebo- Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Jianming Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
481PPhase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial
H Osawa et al.
ANNALS OF ONCOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jeremy C. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
Yasutoshi Kuboki et al.
LANCET ONCOLOGY (2017)
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao et al.
NATURE (2017)
Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
Kuisheng Liu et al.
CELL DEATH & DISEASE (2017)
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Robin M. J. M. van Geel et al.
CANCER DISCOVERY (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
Rui-Hua Xu et al.
CHINESE JOURNAL OF CANCER (2017)
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102
Satoshi Hamauchi et al.
CLINICAL COLORECTAL CANCER (2017)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
D. P. Modest et al.
ANNALS OF ONCOLOGY (2016)
The role of the ALK receptor in cancer biology
B. Hallberg et al.
ANNALS OF ONCOLOGY (2016)
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
Antoine Adenis et al.
BMC CANCER (2016)
Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Evgeny Yakirevich et al.
CLINICAL CANCER RESEARCH (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
Hiroshi Tsukihara et al.
ONCOLOGY REPORTS (2015)
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Jikui Guan et al.
ELIFE (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Cancer Treatment and Survivorship Statistics, 2014
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Two Dimensions in Targeting HER2
Mark M. Moasser
JOURNAL OF CLINICAL ONCOLOGY (2014)
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
Dara L. Aisner et al.
MOLECULAR CANCER RESEARCH (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients
Cen Xie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
Giuseppe Tonini et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation
Jeanne Tie et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The biology and treatment of EML4-ALK non-small cell lung cancer
Takaaki Sasaki et al.
EUROPEAN JOURNAL OF CANCER (2010)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiogenesis in cancer
Naoyo Nishida et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2006)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
